

VARDHAMAN

Vardhaman Laboratories Limited

REGD. OFFICE : 1393, Peth-Bhag, High School Road, P.O.Box 184, SANGLI 416 416.
Tel: (0233) 2623886, 2623310 Fax: (0233) 2620467 E-mail : vll@vsnl.com
FACTORY : J-5, MIDC, Kupwad, SANGLI 416 436.

L85195PN1985PLC036017

15th November, 2017

To,

The Secretary,
Bombay Stock Exchange Limited,
P.J. Towers, Dalal Street,
Mumbai – 400 001

Dear Sirs,

Ref.:- Scrip Code 524796

Sub.:- Submission of Unaudited Financial Results for the quarter & half year ended 30th September, 2017.

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith Unaudited Financial Results of our Company for the quarter and half year ended 30th September, 2017 along with Limited Review Report dated November 15, 2017 issued by M/s. Agrawal Naredi & Co, Statutory Auditors of the Company.

You are requested to take the same on your records.

Yours truly,

For VARDHAMAN LABORATORIES LIMITED



SUNIL SHAH
Managing Director
(DIN:00321471)

Encl.:- As above.

VARDHAMAN LABORATORIES LIMITED


CIN : L85195PN1985PLC036017

REGD.OFFICE-1393,PETH BHAG,HIGH SCHOOL ROAD,SANGLI 416 416 E-MAIL-vll@vsnl.com

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER, 2017							
							(Rs. In Lakhs)
Sr. No.	Particulars	3 Months ended	3 Months ended	Corresponding 3 months ended in the previous year	Year to date figures for the current period ended	Year to date figures for the previous period ended	Previous Year ended
		30/09/2017 Unaudited	30/06/2017 Unaudited	30/09/2016 Unaudited	30/09/2017 Unaudited	30/09/2016 Unaudited	31/03/2017 (Audited)
1	Income from Operations						
	Net Sales/Income from operations	-	-	-	-	-	-
	Other Operating Income	-	-	-	-	-	-
	Total income from operations (net)	-	-	-	-	-	-
2	Expenses						
	(a) Cost of Material Consumed	-	-	-	-	-	-
	(b) Purchase of stock in trade	-	-	-	-	-	-
	(c) Change in inventories of finished goods, work in progress and stock in trade	-	-	-	-	-	-
	(d) Employee Benefits Expenses	-	-	-	-	-	-
	(e) Depreciation and Amortization Expense	-	-	-	-	-	-
	Other Expenses	1.1697	3.4743	2.6922	4.6440	3.9732	7.4195
	Total Expenses	1.1697	3.4743	2.6922	4.6440	3.9732	7.4195
3	Profit/(Loss) from operations before other income, finance cost & Exceptional Item (1-2)	(1.1697)	(3.4743)	(2.6922)	(4.6440)	(3.9732)	(7.4195)
4	Other Income	0.8930	0.8301	0.9257	1.7231	1.8526	3.7018
5	Profit/(Loss) from ordinary activities before finance cost & Exceptional Items (3+/-4)	(0.2767)	(2.6442)	(1.7665)	(2.9209)	(2.1206)	(3.7177)
6	Finance Cost	-	-	-	-	-	-
7	Profit/(Loss) from ordinary activities after finance cost but before Exceptional Item (5+/-6)	(0.2767)	(2.6442)	(1.7665)	(2.9209)	(2.1206)	(3.7177)
8	Exceptional Items	-	-	-	-	-	-
9	Profit/(Loss) from ordinary activities before Tax (7+/-8)	(0.2767)	(2.6442)	(1.7665)	(2.9209)	(2.1206)	(3.7177)
10	Tax Expenses	-	-	-	-	-	-
11	Net Profit/(Loss) from ordinary activities after Tax (9+/-10)	(0.2767)	(2.6442)	(1.7665)	(2.9209)	(2.1206)	(3.7177)
12	Extraordinary Item (Net of Tax)	-	-	-	-	-	-
13	Net Profit/(Loss) for the period (11+/-12)	(0.2767)	(2.6442)	(1.7665)	(2.9209)	(2.1206)	(3.7177)
14	Share of Profit / (loss) of associates	-	-	-	-	-	-
15	Minority interest	-	-	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+/- 14+/-+16)	(0.2767)	(2.6442)	(1.7665)	(2.9209)	(2.1206)	(3.7177)
17	Paid up Equity Share Capital (Face Value of Rs.10/- each)	412.47	412.47	412.47	412.47	412.47	412.47
18	Reserve Excluding Revaluation Reserve as per balancesheet of previous accounting year	-	-	-	-	-	-
19 (i)	Earning per Share (Before Extraordinary items) (of Rs. 10/- each)(not annualised)						
	(a) Basic	(0.01)	(0.06)	(0.04)	(0.07)	(0.05)	(0.09)
	(b) Diluted	(0.01)	(0.06)	(0.04)	(0.07)	(0.05)	(0.09)
19 (ii)	Earning per Share (After Extraordinary items) (of Rs. 10/- each)(not annualised)						
	(a) Basic	(0.01)	(0.06)	(0.04)	(0.07)	(0.05)	(0.09)
	(b) Diluted	(0.01)	(0.06)	(0.04)	(0.07)	(0.05)	(0.09)
Notes :							
<input type="checkbox"/>	The above results were reviewed and recommended by the Audit Committee, for approval by the Board, at its meeting held on November 15, 2017 and were approved and taken on record at the meeting of the Board of Directors of the Company held on that date.						
<input type="checkbox"/>	The Financial results for the quarter and half year ended September 30, 2017 have been subjected to a limited review by the Statutory Auditors of the Company. The limited review report does not contain any qualifications. The limited review report will be filed with the Stock Exchange.						
<input type="checkbox"/>	The Company has only one segment which is Pharmaceuticals. Therefore disclosure relating to segment is not applicable and accordingly not made.						
<input type="checkbox"/>	Figures for previous quarters/period have been regrouped /restated where necessary						

Place : SANGLI
Date : November 15, 2017

For VARDHAMAN LABORATORIES LTD.


 SUNIL SHAH
 Director
 DIN:00321471

VARDHAMAN LABORATORIES LIMITED

CIN : L85195PN1985PLC036017


REGD.OFFICE-1393,PETH BHAG,HIGH SCHOOL ROAD,SANGLI 416 416 E-MAIL-vll@vsnl.com

STANDALONE STATEMENT OF ASSETS AND LIABILITIES			
		As at	As at
PARTICULARS		Half Year End	Previous Year End
		30/09/2017	31-03-2017
		Unaudited	Audited
A Equity And Liabilities			
1	Shareholders' Funds		
	(a) Share Capital	412.47	412.47
	(b) Reserve and Surplus	(211.47)	(208.62)
	© Money received against share		
	Sub-Total - Shareholders' Fund	200.99	203.85
2	Share Application Money pending Allotment	-	-
3	Minority Interest*	-	-
4 Non-Current Liabilities			
	(a) Long Term Borrowings		
	(b) Deferred Tax Liability		
	(c) Other long term liability		
	(d) Long Term Provisions	-	-
	Sub-Total - Non-Current Liabilities	-	-
5 Current Liabilities			
	(a) Short Term Borrowings	-	-
	(b) Trade Payables	-	-
	(c) Other Current Liabilities	2.42	1.20
	(d) Short Term Provisions		
	Sub-Total - Current Liabilities	2.42	1.20
	Total Equity And Liabilities	203.41	205.05
B ASSETS			
1	Non-Current Assets		
	(a) Fixed Assets	-	-
	(b) Goodwill on consolidation		
	(c) Non-Current Investments		
	(d) Deferred Tax Assets		
	(e) Long Term Loans and Advances	-	-
	(f) Other non current assets		
	Sub-Total - Non-Current Assets	-	-
2	Current Assets		
	(a) Current Investment		
	(b) Inventories		
	(c) Trade Receivables	155.55	155.55
	(d) Cash and Cash Equivalents	44.78	48.20
	(e) Short Term Loan and Advances	1.03	0.86
	(f) Other Current Assets	2.04	0.44
	Sub-Total - Current Assets	203.41	205.05
	Total - Assets	203.41	205.05

Notes :	
<input type="checkbox"/>	The above results were reviewed and recommended by the Audit Committee, for approval by the Board, at its meeting held on November 15, 2017 and were approved and taken on record at the meeting of the Board of Directors of the Company held on that date.
<input type="checkbox"/>	The Financial results for the quarter and half year ended September 30, 2017 have been subjected to a limited review by the Statutory Auditors of the Company. The limited review report does not contain any qualifications. The limited review report will be filed with the Stock Exchange.
<input type="checkbox"/>	The Company has only one segment which is Pharmaceuticals. Therefore disclosure relating to segment is not applicable and accordingly not made.
<input type="checkbox"/>	Figures for previous quarters/period have been regrouped /restated where necessary

Place : SANGLI
Date : November 15, 2017

For VARDHAMAN LABORATORIES LTD.


SUNIL SHAH
 Director
 DIN:00321471

AGRAWAL NAREDI & CO.**CHARTERED ACCOUNTANTS**

391, NARAYAN PETH, PUNE- 411 030

DATE -15/11/2017

LIMITED REVIEW REPORT

To the Board of Directors

Vardhaman Laboratories Limited

We have reviewed the accompanying statement of unaudited financial results of M/s. Vardhaman Laboratories Limited for the period ended September 30, 2017 **except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us.** This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards specified under section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements) Regulation, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For AGRAWAL NAREDI & CO.,
Chartered Accountants
Firm Registration No. 122480W



Radhesham Agrawal
Partner
Membership No. 118336
Place: Pune
Date: 15/11/2017

